Repurposing Drugs for Post-COVID-19 Fatigue Syndrome: Methylphenidate, Duloxetine, and Brexpiprazole. | Am J Ther;29(2): e229-e230, 2022 01 03. | MEDLINE

Main content 1 Search 2 Footer 3

+A A -A High contrast

WHO COVID-19 Research Database

News/Update/Help

Advanced Search

The WHO Covid-19 Research Database is a resource created in response to the Public Health Emergency of International Concern (PHEIC). Its content remains searchable and spans the time period March 2020 to June 2023. Since June 2023, manual updates to the database have been discontinued.

Repurposing Drugs for Post-COVID-19 Fatigue Syndrome: Methylphenidate, Duloxetine, and Brexpiprazole.

Manu, Peter.

Manu P; Department of Medicine, Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY and Medical Services, South Oaks Hospital, Amityville, NY.

Am J Ther ; 29(2): e229-e230, 2022 01 03.

Article in English | MEDLINE | ID: covidwho-1752208

Subject(s)

COVID-19; Methylphenidate; COVID-19/complications; Drug Repositioning; Duloxetine Hydrochloride/therapeutic use; Fatigue; Humans; Methylphenidate/therapeutic use; Quinolones; Thiophenes

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Methylphenidate Topics: Long Covid Limits: Humans Language: English Journal: Am J Ther Journal subject: Therapeutics Year: 2022 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Methylphenidate Topics: Long Covid Limits: Humans Language: English Journal: Am J Ther Journal subject: Therapeutics Year: 2022 Document Type: Article